Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)

Phase 2

Active, not recruiting

• Conditions: Rectal adenocarcinoma

• Registration Number: 2024-512855-19-00
• Lead Sponsor: Institut De Cancerologie De L Ouest

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study First Posted: 2024-06-18
• Last Update Posted: 2024-06-18

Recruitment & Eligibility

• Status: Ongoing, recruitment ended
• Sex: All
• Target Recruitment: 70

Inclusion Criteria

Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 56
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 14

Exclusion Criteria

Not provided

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified

Trial Locations

Locations (4)

Institut De Cancerologie De L Ouest; 🇫🇷 Angers, France

Centre Hospitalier Regional Et Universitaire De Brest; 🇫🇷 Brest, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

Centre De Lutte Contre Le Cancer Eugene Marquis; 🇫🇷 Rennes Cedex, France

Institut De Cancerologie De L Ouest

🇫🇷Angers, France

Maëlle LE THIEC

Site contact

+33240679931

maelle.lethiec@ico.unicancer.fr